The subscription window for Accretion Nutraveda Limited opened this morning on the BSE SME platform and will remain active until Friday, January 30, 2026. The issue is entirely a fresh issue of 19.20 lakh equity shares.
Accretion Nutraveda operates as a Contract Development and Manufacturing Organization (CDMO) and also exports directly to international markets including the USA, Singapore, and Sri Lanka. Its portfolio includes over 72 formulations across tablets, capsules, liquids, and oils, focusing on chronic care areas like liver health, cognitive support, and respiratory wellness.
The company plans to utilize ₹12.25 crore of the proceeds for purchasing machinery—both to automate its existing facility and to set up a new manufacturing unit. Financially, the company has seen explosive growth; revenue jumped from ₹5.01 crore in FY24 to ₹16 crore in FY25, while its Profit After Tax (PAT) surged from ₹0.82 crore to ₹2.61 crore in the same period.
As of 10:00 AM today, the Grey Market Premium (GMP) is holding steady at ₹0, indicating a neutral start as investors wait to see the Day 1 subscription momentum.
Key IPO Details & Timetable
| Feature | Details |
| Price Band | ₹122 – ₹129 per share |
| Lot Size | 2,000 Shares (Min. Investment ₹2,58,000) |
| Total Issue Size | ₹24.77 Crore |
| Listing Platform | BSE SME |
| Open Date | January 27, 2026 (Today) |
| Close Date | January 30, 2026 |
| Basis of Allotment | February 2, 2026 |
| Tentative Listing | February 4, 2026 |
Important Note for Investors
-
Exceptional Efficiency: The company boasts a massive Return on Equity (ROE) of 81.22% for FY25. While this is exceptionally high, investors should note that the equity base is small, and these ratios may normalize after the IPO capital infusion.
-
CDMO Business Model: Over 96% of revenue currently comes from domestic sales and merchant exports (loan license basis). While this provides scale, it also means the company is heavily dependent on a few large B2B clients rather than its own retail brand presence.
-
Valuation Watch: At the upper price band of ₹129, the stock is valued at a P/E of approximately 35.75x (post-issue). Some market analysts have labeled this as a "pricey" bet compared to smaller peers in the nutraceutical space.
-
Working Capital Intensive: The company is allocating ₹5.50 crore specifically for working capital. The nutraceutical manufacturing cycle involves long lead times for raw material procurement (herbal extracts), making cash flow management critical.
-
Regulatory Compliance: Since the company deals with Ayurvedic products, any change in AYUSH or FSSAI regulations could impact its production lines or export eligibility to the USA and Singapore.